WuXi Biologics Announces 2017 Interim Results
WuXi Biologics and Gloria Pharmaceuticals Announce the Licensure of the Fully Human PD-1Antibody, GLS-010, to Arcus Biosciences
The U.S. FDA Completed Pre-License Inspection (PLI) of WuXi Biologics cGMP Manufacturing Facilities for Production of TMB-355 (ibalizumab)
WuXi Biologics is Officially Listed on the Hong Kong Stock Exchange
WuXi Biologics Receives Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC
Novel Anti-IL-6 Antibody for Rheumatoid Arthritis from WuXi–MedImmune Joint Venture Receives Clinical Trial Permit (CTP) from CFDA
WuXi Biologics Receives 2016 Asia Pacific Biologics CMO Growth Excellence Leadership Award from Frost & Sullivan
WuXi Biologics and Prima Signs MOU and Announces Strategic Development and Manufacturing Partnership
WuXi Biologics completes construction of Asia’s largest perfusion biologics manufacturing facility using disposable bioreactors
WuXi Biologics Congratulates TESARO for Anti-TIM-3 Antibody IND Submission in the U.S.
See below for other press releases by year.
2016 2015 2014 2013 2012
November 6-8, 2017 | City Cube Berlin
RESI New York
November 15, 2017 | New York, NY
re about WuXi’s truly ONE services
or to receive a quote – Click Here.